ReviewClinical medicine insights. Endocrinology and diabetes2023
Cardiometabolic Risk Factors Associated With Type 2 Diabetes Mellitus: A Mechanistic Insight.
Review in Clinical medicine insights. Endocrinology and diabetes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Digital Health Interventions for Cardiometabolic Health Outcomes in Rural and Remote Australia: A Systematic Review.The Australian journal of rural health · 2025Pooled it
- Effects ofNutrients · 2025Pooled it
- Effect of boswellia (Frontiers in clinical diabetes and healthcare · 2024Pooled it
- Effects of the MIND diet on cardiometabolic health and novel anthropometric measures in women with type 2 diabetes and insomnia: a randomized controlled trial.Nutrition journal · 2025Trial
- Citrus Peel Xanthophylls Orchestrate Lipid-Glucose-Inflammation Axis Reprogramming in Cardiometabolic Syndrome: Integrative In Silico and In Vivo Evidence.Molecular nutrition & food research · 2026Article
- Quantifying the Predictive Power of Social Determinants of Health in Cardiovascular Disease and Type 2 Diabetes Progression Using XGBoost: Retrospective Cohort Study.JMIR medical informatics · 2026Article
- Atherogenic index of plasma and risk of hypertensive disorders of pregnancy in women with gestational diabetes mellitus: a two-center cohort study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Observational
- Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Correlation Between Fasting Blood Glucose and Serum Lipid Profile and Lipid Ratios in Patients with Type 2 Diabetes Mellitus in Southern Thailand: A Cross-Sectional Study.Medical sciences (Basel, Switzerland) · 2026Article
- Integrated LC-MS/MS profiling, network pharmacology, molecular docking, and enzyme inhibition assays reveal the antidiabetic potential ofToxicology reports · 2026Article
- Cardiovascular Disease and Fracture Risk in People with Type 2 Diabetes: A Nationwide Matched Case-Control Study.Calcified tissue international · 2026Article
- Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review.Journal of bone metabolism · 2026Article
- Lifestyle and Health Characteristics of the Adult Population of Serbia with Type 2 Diabetes Mellitus.Medicina (Kaunas, Lithuania) · 2026Article
- Longitudinal cohort study on the dynamic changes of atherogenic index of plasma and the risk of cardiometabolic multimorbidity in middle - aged and elderly people.BMC cardiovascular disorders · 2026Article
- The joint association of the combined triglyceride-glucose index and atherogenic index of plasma with hypertension on stroke risk across different glycemic status: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Fasting blood glucose trajectories and atherosclerosis risk: a longitudinal cohort study with threshold analysis in Chongqing, China.Journal of health, population, and nutrition · 2026Article
- Metabolic Syndrome Predisposes Ossabaw Minipig Retina to an Early Neurodegenerative Milieu.Cells · 2026Article
- Determinants of inflammatory and adipokine biomarkers in obese young women: The role of skeletal muscle and lifestyle factors in Indonesia.Journal of education and health promotion · 2026Article
- Association of pericoronary fat attenuation index and insulin resistance for the risk of cardiometabolic multimorbidity: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Real-World Effectiveness and Safety of Imeglimin in Type 2 Diabetes: Prospective Multi-Center Study in Bangladesh.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A complex metabolic condition referred to as Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance (IR) and decreased insulin production. Obesity, dyslipidemia, hypertension, and chronic inflammation are just a few of the cardiometabolic illnesses that people with T2DM are more likely to acquire and results in cardiovascular issues. It is essential to comprehend the mechanistic insights into these risk variables in order to prevent and manage cardiovascular problems in T2DM effectively. Impaired glycemic control leads to upregulation of De novo lipogenesis (DNL), promote hepatic triglyceride (TG) synthesis, worsening dyslipidemia that is accompanied by low levels of high density lipoprotein cholesterol (HDL-C) and high amounts of small, dense low-density lipoprotein cholesterol (LDL-C) further developing atherosclerosis. By causing endothelial dysfunction, oxidative stress, and chronic inflammation, chronic hyperglycemia worsens already existing cardiometabolic risk factors. Vasoconstriction, inflammation, and platelet aggregation are caused by endothelial dysfunction, which is characterized by decreased nitric oxide production, increased release of vasoconstrictors, proinflammatory cytokines, and adhesion molecules. The loop of IR and endothelial dysfunction is sustained by chronic inflammation fueled by inflammatory mediators produced in adipose tissue. Infiltrating inflammatory cells exacerbate inflammation and the development of plaque in the artery wall. In addition, the combination of chronic inflammation, dyslipidemia, and IR contributes to the emergence of hypertension, a prevalent comorbidity in T2DM. The ability to target therapies and management techniques is made possible by improvements in our knowledge of these mechanistic insights. Aim of present review is to enhance our current understanding of the mechanistic insights into the cardiometabolic risk factors related to T2DM provides important details into the interaction of pathophysiological processes resulting in cardiovascular problems. Understanding these pathways will enable us to create efficient plans for the prevention, detection, and treatment of cardiovascular problems in T2DM patients, ultimately leading to better overall health outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.